Epidermal growth factor
Epidermal growth factor (EGF) is a single-chain polypeptide of 6045 daltons, from submandibular glands of male mice. EGF binds to specific cell surface receptors to elicit diverse biological actions both in vivo and in vitro, including cell proliferation and regulation of differentiated cellular functions.
In recent studies, it was reported that EGF is present in the uterine luminal fluid in the rat (Imai 1982) and in the mouse uterus. (Gonzalez et al., 1984) . Moreover, the presence of EGF receptors was demonstrated in the rat and in the human myometrium (Hofmamm et al., 1984 Recently, it was suggested that certain growth factors mediate estrogen action in inducing cell division in estrogen stimulated target cells. For instance, insulinlike growth factor or EGF-like peptides were detected in the conditioned medium of human breast cancer cells cultured with estrogen (Lippman et al., 1984) . Furthermore, according to the results of a more recent study, the mouse uterus is shown to contain considerable amounts of EGF, the levels of which are elevated by estrogen (DiAugustine et al., 1985) . Taking the results of these observations together, it is tempting to speculate that EGF may be involved in estrogen stimulated uterine growth.
Mukku et al. have reported that the administration of estradiol to immature female rats produces a 3-fold increase in EGF binding to uterine membrane with no change in the affinity of membrane receptors for EGF (Mukku et al., 1985) . It was also shown that the effect of estradiol is specific in that other steroid hormones fail to increase the number of the receptors. These steroids may take part in the alteration of EGF receptors in the endometrium as shown here. Preliminary studies of a primary cell culture of human endometrium demonstrated the increase in the binding of EGF to endometrial cells cultured in the presence of estradiol.
Another example of the regulation of EGF receptors by steroid hormones is the increased ability of human fibroblasts to bind EGF in the presence of dexamethasone (Baker et al., 1978) . Progestin is also known to increase EGF receptors in a certain cell line of human breast cancer (Murphy et al., 1985) .
The induction of EGF receptors by estrogen occurs between 6 and 12 hours after the hormone administration whereas DNA synthesis begins approximately 18-24 hours after the treatment (Mukku et al., 1985) . Thus, the increase in EGF receptors precedes the DNA synthesis. Another line of evidence indicates that several events occurring between 6 and 12 hours after the estrogen treatment play a critical role in inducing uterine growth (Anderson et al., 1975 , Harris et al., 1978 . These findings further suggest a possible role of EGF in mediating a mitogenic action of estrogen.
Gonzalez et al. have revealed that the sequential injection of estradiol to immature mice effects an increases in uterine weight and the concentrations of EGF in the uterus (Gonzales et al., 1984) . However, the EGF concentration in the submandibular gland is unaltered by estradiol. The submandibular gland is thought to be a major source of EGF. Recent studies imply that EGF is produced in some tissues other than the submandibular gland, such as the kidney and the pancreas (Rall et al., 1985) . More recently, messenger RNA for EGF was detected in the uterus of ovariectomized rats (Teng et al., 1985) , and the levels of the messenger RNA are augmented by estrogen treatment in keeping with the findings of Gonzales et al. 
